TfR-Binding siRNA Conjugates for Targeted Ocular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering interfering RNA molecules in vivo are inefficient and lack specificity, leading to off-target effects and immune responses, limiting their therapeutic potential for treating ocular disorders.
Innovation Solution
Development of interfering RNA-ligand conjugates that bind to the transferrin receptor (TfR) on eye cells, using ligands such as peptides, antibodies, and aptamers to facilitate targeted delivery of interfering RNA molecules into eye cells, enabling effective treatment of ocular disorders like ocular angiogenesis, dry eye, and glaucoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interfering RNA is delivered using conventional methods (naked, polycations, cationic lipids), then delivery can be achieved, but specificity is poor and off-target effects occur
Solution Approach 1:
The patent uses transferrin receptor-binding ligands as intermediaries to mediate the delivery of interfering RNA to target cells. The ligand acts as a bridge that specifically recognizes and binds to transferrin receptors on the surface of target cells, thereby directing the interfering RNA to the intended destination and reducing off-target effects.
Solution Approach 2:
The patent applies local quality by functionalizing the interfering RNA delivery system with specific ligands that bind to transferrin receptors. This creates a localized, targeted delivery mechanism where only cells expressing the transferrin receptor are affected, providing spatial and cellular specificity to the RNA interference therapy.
2Reliability
If interfering RNA is delivered using conventional methods, then delivery can be achieved, but immune responses are triggered
Solution Approach 1:
The transferrin receptor-binding ligand serves as a protective intermediary that shields the interfering RNA from immune recognition. By using this specific ligand as a delivery vehicle, the patent reduces the immunogenicity of the interfering RNA while maintaining delivery efficiency to target cells.
Solution Approach 2:
The patent changes the physical and chemical parameters of the interfering RNA delivery system by conjugating it to transferrin receptor-binding ligands. This modification alters the immunogenic properties of the interfering RNA, reducing immune response while preserving its gene-silencing function.
3Device complexity
If interfering RNA is delivered without targeted ligands, then delivery is simpler, but therapeutic potential is limited
Solution Approach 1:
The patent employs transferrin receptor-binding ligands that provide multi-functionality: they enable specific cell targeting, facilitate cellular uptake, and protect the interfering RNA from degradation. This universal approach enhances therapeutic potential while maintaining reasonable system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TfR-binding conjugates enhance the specificity and efficacy of interfering RNA delivery, reducing off-target effects and immune responses, allowing for effective attenuation of target gene expression in eye cells, thereby treating ocular disorders with improved therapeutic outcomes.
Implementation Method 1
The conjugates comprise a ligand that can bind to a transferrin receptor (TfR)
Data Source
AI summary
The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.